In published preclinical research, Epithalon has been administered across rodent, fly, and cell-culture model systems with intraperitoneal, subcutaneous, and intranasal routes characterised across the literature (PMID 11087911, PMID 17955380, PMID 35413689)
Ultra-High 5% Concentration for Radical Transformation While standard creams use less than 0.5%, our 5% Blue Copper Peptide (GHK-Cu) Cream is an intensive treatment designed for maximum efficacy
By controlling inflammation, the peptide creates a more favorable environment for tissue repair and reduces the risk of scarring or chronic injury
This activation results in numerous changes in cells, including the production of TNF, IL-1, and IL-6, which are pro-inflammatory cytokines with various effects on the host
Subtle improvements in sleep quality Reduced morning stiffness Slightly improved activity tolerance Possible temporary sensitivity at injury sites Gradual reduction in baseline discomfort Progressive Phase (Weeks 4 to 8) The middle phase of treatment typically brings more noticeable improvements
DSIP is not a direct sedative and may normalize stages instead